• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Respirology . IL-17A is a common and critical driver of impaired lung function and immunopathology induced by influenza virus, rhinovirus and respir

tetano

Editor, Senior Moderator
Respirology


. 2021 Sep 1.
doi: 10.1111/resp.14141. Online ahead of print.
IL-17A is a common and critical driver of impaired lung function and immunopathology induced by influenza virus, rhinovirus and respiratory syncytial virus


Xiaoming Liu[SUP] 1 2 [/SUP], Thi Hiep Nguyen[SUP] 1 2 [/SUP], Leon Sokulsky[SUP] 1 [/SUP], Xiang Li[SUP] 1 2 [/SUP], Keilah Garcia Netto[SUP] 1 2 [/SUP], Alan Chen-Yu Hsu[SUP] 2 3 4 [/SUP], Chi Liu[SUP] 5 [/SUP], Karen Laurie[SUP] 6 [/SUP], Ian Barr[SUP] 6 [/SUP], Hock Tay[SUP] 1 2 [/SUP], Fiona Eyers[SUP] 1 2 [/SUP], Paul S Foster[SUP] 1 2 [/SUP], Ming Yang[SUP] 1 2 [/SUP]



Affiliations

Abstract

Background and objective: Influenza virus (FLU), rhinovirus (RV) and respiratory syncytial virus (RSV) are the most common acute respiratory infections worldwide. Infection can cause severe health outcomes, while therapeutic options are limited, primarily relieving symptoms without attenuating the development of lesions or impaired lung function. We therefore examined the inflammatory response to these infections with the intent to identify common components that are critical drivers of immunopathogenesis and thus represent potential therapeutic targets.
Methods: BALB/c mice were infected with FLU, RV or RSV, and lung function, airway inflammation and immunohistopathology were measured over a 10-day period. Anti-IL-17A mAb was administered to determine the impact of attenuating this cytokine's function on the development and severity of disease.
Results: All three viruses induced severe airway constriction and inflammation at 2 days post-infection (dpi). However, only FLU induced prolonged inflammation till 10 dpi. Increased IL-17A expression was correlated with the alterations in lung function and its persistence. Neutralization of IL-17A did not affect the viral replication but led to the resolution of airway hyperresponsiveness. Furthermore, anti-IL-17A treatment resulted in reduced infiltration of neutrophils (in RV- and FLU-infected mice at 2 dpi) and lymphocytes (in RSV-infected mice at 2 dpi and FLU-infected mice at 10 dpi), and attenuated the severity of immunopathology.
Conclusion: IL-17A is a common pathogenic molecule regulating disease induced by three prevalent respiratory viruses. Targeting the IL-17A pathway may provide a unified approach to the treatment of these respiratory infections alleviating both inflammation-induced lesions and difficulties in breathing.

Keywords: IL-17A; airway inflammation; immunopathology; influenza virus; respiratory virus; rhinovirus and respiratory syncytial virus; viral infection.
 
Back
Top Bottom